MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

79.44 -2.68

Resumen

Variación precio

24h

Actual

Mínimo

78.52

Máximo

81.81

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+13.48% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

13B

Apertura anterior

82.12

Cierre anterior

79.44

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 23:54 UTC

Charlas de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ene 2026, 23:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ene 2026, 21:56 UTC

Charlas de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ene 2026, 20:54 UTC

Ganancias

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ene 2026, 20:48 UTC

Charlas de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ene 2026, 20:33 UTC

Charlas de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ene 2026, 19:39 UTC

Charlas de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 19:33 UTC

Charlas de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ene 2026, 19:24 UTC

Adquisiciones, fusiones, absorciones

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ene 2026, 19:22 UTC

Adquisiciones, fusiones, absorciones

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ene 2026, 18:21 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ene 2026, 18:20 UTC

Adquisiciones, fusiones, absorciones

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ene 2026, 18:19 UTC

Charlas de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ene 2026, 18:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ene 2026, 18:01 UTC

Adquisiciones, fusiones, absorciones

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ene 2026, 18:00 UTC

Charlas de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

13.48% repunte

Estimación a 12 meses

Media 92.67 USD  13.48%

Máximo 110 USD

Mínimo 65 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

13

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

173 / 370 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat